Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip G Febbo

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Neoplasia (New York, N.Y.)|March 15, 2006
Defining aggressive prostate cancer using a 12-gene modelTarek A Bismar, Francesca Demichelis, Alberto Riva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expressionCarey K Anders, David S Hsu, Gloria Broadwater, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2018
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant SunitinibBrian I Rini, Bernard Escudier, Jean-Francois Martini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2017
Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology WorkshopKevin S Hughes, Edward P Ambinder, Gregory P Hess, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 6, 2011
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncologyPhillip G Febbo, Marc Ladanyi, Kenneth D Aldape, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancerDavid S Hsu, Bala S Balakumaran, Chaitanya R Acharya, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 29, 2011
NCCN molecular testing white paper: effectiveness, efficiency, and reimbursementPaul F Engstrom, Mara G Bloom, George Daniel Demetri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)Andrew B Nixon, Susan Halabi, Yingmiao Liu, et al.
The Journal of Urology|November 18, 2011
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate CenterSuzanne Biehn Stewart, Lionel L Bañez, Cary N Robertson, et al.
European Urology|December 4, 2014
A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate CancerJennifer Cullen, Inger L Rosner, Timothy C Brand, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Neoplasia (New York, N.Y.)|March 15, 2006
Defining aggressive prostate cancer using a 12-gene modelTarek A Bismar, Francesca Demichelis, Alberto Riva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2008
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expressionCarey K Anders, David S Hsu, Gloria Broadwater, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2018
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant SunitinibBrian I Rini, Bernard Escudier, Jean-Francois Martini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2017
Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology WorkshopKevin S Hughes, Edward P Ambinder, Gregory P Hess, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 6, 2011
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncologyPhillip G Febbo, Marc Ladanyi, Kenneth D Aldape, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancerDavid S Hsu, Bala S Balakumaran, Chaitanya R Acharya, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 29, 2011
NCCN molecular testing white paper: effectiveness, efficiency, and reimbursementPaul F Engstrom, Mara G Bloom, George Daniel Demetri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)Andrew B Nixon, Susan Halabi, Yingmiao Liu, et al.
The Journal of Urology|November 18, 2011
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate CenterSuzanne Biehn Stewart, Lionel L Bañez, Cary N Robertson, et al.
European Urology|December 4, 2014
A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate CancerJennifer Cullen, Inger L Rosner, Timothy C Brand, et al.
Pageof 8